Tools for Practice Outils pour la pratique

#210 Blazing Through the Evidence on THC Versus CBD Combinations in Medical Cannabinoids.

Do tetrahydrocannabinol (THC), cannabidiol (CBD), or the THC/CBD combination yield differing benefits or harms?

From four randomized controlled trials (RCT), one found THC/CBD superior to THC but this was inconsistent within study and with other studies. Adverse events are prevalent in THC/CBD and individual components. While some early poor-quality research in healthy users suggest CBD may attenuate some psychiatric effects of THC, better research in real patients is needed to verify any benefits of specific components.

CFPCLearn Logo

Reading Tools for Practice Article can earn you MainPro+ Credits

La lecture d'articles d'outils de pratique peut vous permettre de gagner des crédits MainPro+

Join Now S’inscrire maintenant

Already a CFPCLearn Member? Log in

Déjà abonné à CMFCApprendre? Ouvrir une session

Identified four RCTs comparing THC, CBD, or combined. 
  • RCT: 243 terminal cancer and weight loss patients, comparing THC/CBD versus THC versus placebo over six weeks.1 
    • THC/CBD versus THC: No statistical difference in appetite or adverse events. 
  • RCT: 177 refractory cancer pain patients on strong opioids (~270 mg morphine), comparing THC/CBD versus THC versus placebo over two weeks.2 
    • 30% pain reduction38% THC/CBD versus 21% THC, Number Needed to Treat=6. 
      • No difference for ≥10% or ≥50% pain reduction. 
    • Adverse events: No difference with THC/CBD versus THC. 
  • RCT: 48 brachial nerve injury patients, comparing THC/CBD versus THC versus placebo over two weeks.3 
    • Baseline pain 7.5/10: Both THC/CBD and THC groups reduced pain ~1.3 points, statistically significantly more than 0.6 with placebo. 
    • Adverse events not significantly different between THC/CBD and THC. 
  • ‘N of 1’ RCT: 24 chronic pain patients who benefitted from THC/CBD, compared THC/CBD versus THC versus CBD versus placebo over eight weeks.4 
    • Patients reporting equal/better pain management versus original THC/CBD.   
      • 38% THC/CBD, 33% THC, 17% CBD: Not statistically different.  
  • RCT 120 Dravet syndrome pediatric patients: CBD reduced seizure frequency ~22% over placebo at 14 weeks.5 
    • Adverse events include somnolence (Number Needed to Harm (NNH)=4), diarrhea (NNH=5), and appetite loss (NNH=5). 
    • Recent RCT of lennox-gastaut (seizure) syndrome adults found similar.6  
  • Canadian guideline recommends cannabinoids only in refractory neuropathic pain, palliative cancer pain, chemotherapy-associated nausea/vomiting, and spasticity.7 
  • One guideline recommends low THC or high CBD:THC ratios to diminish THC adverse events.8 
    • Largely based on small studies of healthy volunteers (some with other drug use history) examining MRI or short-term scale changes.   

Latest Tools for Practice
Derniers outils pour la pratique

#367 Oral Calcitonin Gene-related Peptide Antagonists: A painfully long name for the acute treatment of migraines

What are the risks and benefits of ubrogepant for the acute treatment of episodic migraines?
Read Lire 0.25 credits available Crédits disponibles

#366 Looking for Closure: Managing simple excisions or wounds efficiently

What are some options for efficiency in wound closure?
Read Lire 0.25 credits available Crédits disponibles

#365 Shrooms for Glooms: Evidence for psilocybin for depression

What are the benefits and harms of psilocybin for treatment-resistant/recurrent depression?
Read Lire 0.25 credits available Crédits disponibles

This content is certified for MainPro+ Credits, log in to access

Ce contenu est certifié pour les crédits MainPro+, Ouvrir une session

  • Danielle Perry RN
  • Joey Ton PharmD
  • G. Michael Allan MD CCFP

1. Strasser F, Luftner D, Possinger L, et al. J Clin Oncol. 2006; 24(21):3394-400.

2. Johnson JR, Burnell-Nugent M, Lossignol D, et al. J Pain Symptom Manage. 2010; 39(2):167-79.

3. Berman J, Symonds C, Birch R. Pain. 2004; 112(3):299-306.

4. Notcutt W, Price M, Miller R, et al. Anaesthesia. 2004; 59(5):440-52.

5. Devinsky O, Cross JH, Laux L, et al. N Engl J Med. 2017; 376(21):2011-20.

6. Thiele EA, Marsh ED, French JA, et al. Lancet. 2018; 391:1085-96.

7. Allan GM, Ramji J, Perry D, et al. Can Fam Physician. 2018; 64(2):111-20.

8. Fischer B, Russell C, Sabioni P, et al. Am J Public Health. 2017 Aug; 107(8):1277.

Authors do not have any conflicts of interest to declare.

Les auteurs n’ont aucun conflit d’intérêts à déclarer.